Clinical trials: IgA Nephropathy (IgAN), open to volunteers

IgA Nephropathy (IgAN)

Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

• Not yet recruiting
• Age: 18 to 75 years
• Phase 2
• Pill or oral medicine

Efficacy and safety of MY008211A in IgAN patients

Trial name

NCT06687174

Testing

MY008211A tablets

Where

China

Volunteers

72 people

Sponsor

Wuhan Createrna Science and Technology Co., Ltd